Lung cancer survival time taking osimertinib/osimertinib

Osimertinib/Osimertinib (Osimertinib), as a targeted therapy, has shown a significant survival prolongation effect in patients with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Clinical trial results show that compared with traditional chemotherapy, patients treated with osimertinib/osimertinib have significant advantages in progression-free survival and overall survival. For EGFRgene mutation-positive NSCLC patients, osimertinib/osimertinib is usually used as a first-line treatment drug. Studies have shown that compared with the use of first- and second-generation EGFR tyrosine kinase inhibitors, osimertinib can significantly prolong progression-free survival and improve overall survival. In addition, Osimertinib/Osimertinib also showed efficacy against EGFR T790Mpositive drug resistance NSCLC.